Načítá se...
Complement Inhibition for the Treatment of Myasthenia Gravis
Generalized myasthenia gravis (gMG) is a rare autoimmune disorder affecting the neuromuscular junction (NMJ). Approximately 80–90% of patients display antibodies directed against the nicotinic acetylcholine receptor (AChR). A major drive of AChR antibody-positive MG pathology is represented by compl...
Uloženo v:
| Vydáno v: | Immunotargets Ther |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Dove
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7751298/ https://ncbi.nlm.nih.gov/pubmed/33365280 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/ITT.S261414 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|